Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP3 | P42574 | 16/20 | 0.46 |
| ▸ | CASP7 | P55210 | 15/20 | 0.46 |
| ▸ | CASP9 | P55211 | 1/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.44 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | MCOLN3 | Q8TDD5 | 1/20 | 0.43 |
| ▸ | CASP1 | P29466 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6564147 | 0.89 | CASP3 (0.45) | CASP3CASP7CASP9KCNH2HRH3 | |
| SCHEMBL6139039 | 0.83 | CASP3 (0.35) | CASP3CASP7CASP9KCNH2HRH3 | |
| SCHEMBL2768975 | 0.83 | CASP3 (0.35) | CASP3CASP7CASP9KCNH2HRH3 | |
| SCHEMBL2769590 | 0.83 | CASP3 (0.35) | CASP3CASP7CASP9KCNH2HRH3 | |
| SCHEMBL6564173 | 0.80 | CASP3 (0.46) | CASP3ALDH1A1KMT2A | |
| SCHEMBL8485172 | 0.77 | CASP3 (0.56) | CASP3CASP7CASP9KCNH2HRH3 | |
| SCHEMBL6563959 | 0.77 | CASP3 (0.45) | CASP3CASP7CASP9KCNH2HRH3 | |
| SCHEMBL6137742 | 0.76 | VCAM1 (0.36) | CASP3CASP7CASP9ALDH1A1KMT2A | |
| SCHEMBL2768514 | 0.76 | VCAM1 (0.36) | CASP3CASP7CASP9ALDH1A1KMT2A | |
| SCHEMBL2768872 | 0.76 | VCAM1 (0.36) | CASP3CASP7CASP9ALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1161232-B1 | HYDROXY DIPHENYL UREA SULFONAMIDES AS IL-8 RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORP (US) | 2004-03-24 | — | — | EP | disclosed |
| US-20030109527-A1 | Hydroxy diphenyl urea sulfonamides as IL-8 receptor antagonists | SMITHKLINE BEECHAM CORPORATION | 2003-06-12 | — | — | US | disclosed |
| US-6500863-B1 | INTERLEUKIN BINDING INHIBITORS SUCH AS N-(2-HYDROXYL-3-AMINO SULFONYL-4-CHLOROPHENYL)-N'-(2-BROMOPHENYL)UREA, USED FOR PROPHYLAXIS OF CHEMOKINE MEDIATED DISEASES | SMITHKLINE BEECHAM CORPORATION | 2002-12-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030109527-A1 | Hydroxy diphenyl urea sulfonamides as IL-8 receptor antagonists | CXCL8, CCR8, IL18 | CASP3 1780/4885CASP7 1342/4885CASP9 1057/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.